Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single Anti-Inflammatory injection boost jaw joint relief?

NCT ID NCT07743684

Disease control Sponsor: Hussein Mohammed Ridha Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This trial tests whether adding a single injection of the anti-inflammatory drug meloxicam to a standard jaw joint washout procedure (arthrocentesis) improves outcomes for people with painful jaw joint problems. Half of the 50 adult participants will receive the combined treatment, while the other half will receive arthrocentesis alone. Over 12 weeks, researchers will measure pain, how wide the mouth can open, joint sounds, and patient satisfaction to see if the added drug makes a meaningful difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Arthrocentesis (joint washout) followed by a single intra-articular injection of meloxicam, an anti-inflammatory drug
What this could lead to
If adding meloxicam to arthrocentesis works, it could offer a more effective, minimally invasive treatment for stubborn TMJ pain and jaw stiffness, potentially reducing the need for more invasive surgery.
What could go wrong
This is a small, early-stage trial with only 50 participants, so results may not apply broadly. The benefit of adding meloxicam might be modest or no better than arthrocentesis alone, and there is a small risk of injection-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients \>= 18 years diagnosed clinically with unilateral TMJ internal derangement with or without reduction, based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). * Failure of conservative therapy (splint therapy, physiotherapy) for at least 1 month. * Willing and able to provide written informed consent. Exclusion Criteria: * Patients with bilateral TMJ internal derangement. * History of TMJ surgery or major trauma on the affected side. * Presence of rheumatic disease. * Severe degenerative joint disease. * Active infection around the TMJ. * Known bleeding disorders or patients on anticoagulant therapy. * Pregnancy or lactation. * Allergy to Meloxicam or its components. * Received intra-articular injections (corticosteroids, hyaluronic acid) in the TMJ within at least 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Temporomandibular joint internal derangement are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

temporomandibular joint dysfunction syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Temporomandibular joint internal derangement

Contacts and locations

Locations

  • Al-Yarmook teaching hospital

    Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.